ZA200206349B - Use of CDP-Choline for the treatment of alcohol withdrawal syndrome. - Google Patents

Use of CDP-Choline for the treatment of alcohol withdrawal syndrome. Download PDF

Info

Publication number
ZA200206349B
ZA200206349B ZA200206349A ZA200206349A ZA200206349B ZA 200206349 B ZA200206349 B ZA 200206349B ZA 200206349 A ZA200206349 A ZA 200206349A ZA 200206349 A ZA200206349 A ZA 200206349A ZA 200206349 B ZA200206349 B ZA 200206349B
Authority
ZA
South Africa
Prior art keywords
acid
choline
cdp
pharmaceutically acceptable
salts
Prior art date
Application number
ZA200206349A
Other languages
English (en)
Inventor
Rafael Foguet
Jorge Ramentol
Rafael Lozano
Julian Agut
Jesus Torres
Manuel M Raga
Josep M Castello
Jose A Ortiz
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of ZA200206349B publication Critical patent/ZA200206349B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200206349A 2000-03-29 2002-08-08 Use of CDP-Choline for the treatment of alcohol withdrawal syndrome. ZA200206349B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000765A ES2170649B1 (es) 2000-03-29 2000-03-29 Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.

Publications (1)

Publication Number Publication Date
ZA200206349B true ZA200206349B (en) 2003-08-08

Family

ID=8492914

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200206349A ZA200206349B (en) 2000-03-29 2002-08-08 Use of CDP-Choline for the treatment of alcohol withdrawal syndrome.

Country Status (21)

Country Link
US (1) US6894032B2 (https=)
EP (1) EP1267892B1 (https=)
JP (1) JP4724348B2 (https=)
KR (1) KR100794891B1 (https=)
AT (1) ATE281172T1 (https=)
AU (2) AU2001262141B2 (https=)
BR (1) BR0109477A (https=)
CA (1) CA2402707C (https=)
CZ (1) CZ298933B6 (https=)
DE (1) DE60106890T2 (https=)
DK (1) DK1267892T3 (https=)
ES (1) ES2170649B1 (https=)
IL (2) IL151163A0 (https=)
MX (1) MXPA02009442A (https=)
NO (1) NO329766B1 (https=)
NZ (1) NZ520825A (https=)
PL (1) PL199291B1 (https=)
PT (1) PT1267892E (https=)
RU (1) RU2251422C2 (https=)
WO (1) WO2001072288A2 (https=)
ZA (1) ZA200206349B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
AU2003252488A1 (en) * 2002-07-11 2004-02-02 Yamasa Corporation Medicinal composition for drug-induced neuropathy
BR0316054A (pt) 2002-11-08 2005-09-20 Mclean Hospital Corp Compostos para tratamento de dependência e privação de tabaco
JP4717444B2 (ja) * 2002-12-20 2011-07-06 ザ マクレーン ホスピタル コーポレーション 睡眠／覚醒サイクルの正規化のための化合物
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
US7947661B2 (en) 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
RU2072239C1 (ru) * 1991-01-11 1997-01-27 Институт биохимии СО РАМН Способ коррекции метаболической зависимости от алкоголя и средство л.е.панина для его осуществления
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
JP4408450B2 (ja) * 1994-07-01 2010-02-03 ウェルスタット セラピューティクス コーポレイション 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
KR100217488B1 (ko) * 1997-06-03 1999-09-01 맹섭 골프채의 헤드커버
RU2127589C1 (ru) * 1997-06-03 1999-03-20 Порембский Ярослав Олегович Способ лечения стрессорных поражений нервной системы
US5958896A (en) 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
KR100794891B1 (ko) 2008-01-14
ES2170649B1 (es) 2003-06-16
JP4724348B2 (ja) 2011-07-13
US20030162749A1 (en) 2003-08-28
WO2001072288A3 (en) 2002-05-10
JP2003528133A (ja) 2003-09-24
ATE281172T1 (de) 2004-11-15
WO2001072288A2 (en) 2001-10-04
ES2170649A1 (es) 2002-08-01
MXPA02009442A (es) 2003-02-12
CA2402707A1 (en) 2001-10-04
BR0109477A (pt) 2003-06-03
NO329766B1 (no) 2010-12-13
AU2001262141B2 (en) 2005-03-10
CZ20023245A3 (cs) 2003-03-12
PL363177A1 (en) 2004-11-15
PL199291B1 (pl) 2008-09-30
CZ298933B6 (cs) 2008-03-12
PT1267892E (pt) 2005-03-31
AU6214101A (en) 2001-10-08
DK1267892T3 (da) 2005-03-07
NO20024574L (no) 2002-11-22
DE60106890D1 (de) 2004-12-09
IL151163A (en) 2011-01-31
IL151163A0 (en) 2003-04-10
RU2002129579A (ru) 2004-03-27
EP1267892B1 (en) 2004-11-03
NZ520825A (en) 2004-04-30
NO20024574D0 (no) 2002-09-24
DE60106890T2 (de) 2005-11-03
EP1267892A2 (en) 2003-01-02
CA2402707C (en) 2007-11-13
US6894032B2 (en) 2005-05-17
KR20030005248A (ko) 2003-01-17
RU2251422C2 (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
D'Orlando et al. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury
AU725249B2 (en) Use of a thienotriazolodiazepine to increase apolipoprotein A-I levels
KR20020031331A (ko) 미토콘드리아 관련 질환의 치료방법
WO2001078704A2 (en) Gaba substrate and the use thereof for treating cognitive and emotional disorders
CA2402707C (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
JP3942207B2 (ja) うつ性症状改善剤
CN103599115B (zh) 一种组合物在制备抗癫痫药物中的应用
ES2249616T3 (es) Citidina-fosfocolina para el tratamiento de la neuropatia diabetica.
CN111184731A (zh) 人参皂苷Rg5在制备用于改善睡眠的药物组合物中的用途
EP1383579B1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
CN118203111A (zh) 用于偏头痛的预防和治疗的食品补充剂
KR20030019444A (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
EP1765364A1 (en) Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
CN100358533C (zh) 用于药物诱导的神经病的药物组合物
CN1562345A (zh) 包含脑代谢激活剂和自由基清除剂的联合用药物
AU2001282510A1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
WO2009093735A1 (ja) 医薬組成物